Allergic rhinitis with chronic sinusitis and nasal polyps
Conditions
Interventions
Control group:Anti-infection therapy was given for 3 days after CRS. Mometasone furoate nasal spray for 3 months
at the same time, the nasal cavity was irrigated with sea salt water, and mucous stimulating agent was taken orally for 4 weeks.
Experimental group:After CRS, in addition to the above drug therapy, combined with oral splenic aminopeptide solution, medication was given for 3 months.
Sponsors
Beijing Tongren Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. CRSwNP meets the diagnostic criteria of the Chinese guidelines for the diagnosis and treatment of chronic sinusitis (2018); 2. Patients with allergic rhinitis, the diagnosis of allergic rhinitis meets the diagnostic criteria of "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis" (2015); 3. Age 18-65 years old, male or female; 4. Patients undergoing nasal endoscopic surgery; 5. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with benign and malignant tumors of the nasal cavity and sinuses; 2. Patients with a history of nasal endoscopic surgery; 3. Patients have been treated with oral/nasal glucocorticoids and oral/nasal antihistamines within 4 weeks before enrollment; 4. Those with obvious liver, heart, kidney, respiratory system, blood system, nervous system, and metabolic diseases in the past or at present; 5. Patients with psychological barriers and mental illnesses that the researchers judged could not be included in the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total clinical response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Nasal sinus outcome test -22 score;Sinus CT scan with Lund-Mackay score;Nasal endoscopy Lund-Kennedy score;Peripheral blood/nasal secretions EOS;Cytokines in peripheral blood/nasal secretions;Recurrence rate;Symptom score; | — |
Countries
China
Contacts
Public ContactWang Xiangdong
Beijing First Biochemical Pharmaceutical Co., Ltd.
Outcome results
None listed